curriculum vitae - tabula rasa healthcare€¦ · 2011/04 certificate program of predictive and...

CURRICULUM VITAE VERONIQUE MICHAUD, B.SC. PHARM., Ph.D.

Tabula Rasa HealthCare (TRHC)

TRHC Scientific Precision Pharmacotherapy Research & Development Institute (SPPRDI)

Chief Operating Officer

13485 Veteran’s Way, Lake Nona, Orlando, FL, 32827

Phone number: 407-454-9964

Email: [email protected]

Actual Position

2019/01 – Chief operating officer TRHC Scientific Precision Pharmacotherapy Research &

Development Institute Lake Nona, Orlando, FL

2017/08 – Adjunct professor, Indiana University School of medicine, Clinical Pharmacology Department Indianapolis, IN

2016/09 – Adjunct professor, Associate Researcher position CRCHUM Faculté de Pharmacie, Université de Montréal, Montreal, Que, Canada

Previous Positions

2018/01 –2018/12 Associate professor

College of Pharmacy, University of Florida

Pharmacotherapy and Translational Research Department

Lake Nona, Orlando, FL, USA

2016/10 – 2017/12 V.P. Scientific Affairs, TabulaRasa Health Care Moorestown, NJ, USA 2012/04 – 2016/09 Assistant professor, Full Researcher position CRCHUM Faculté de Pharmacie, Université de Montréal, Montreal, Que, Canada

2014 – 2017 Scientific Director Pharmacokinetic and Bioanalytic core facility CRCHUM Montreal, Que, Canada

mailto:[email protected]

V.Michaud, BPharm., PhD. C.V. June 2020

2

Educational Background

1997/09 – 2001/05 B.Sc. Pharmacy, Faculté de Pharmacie, Université Laval, Ste-Foy, Québec.

2001/09 – 2003/12 M.Sc., Faculté de Pharmacie, Université de Montréal, Montreal, Quebec.

2004/01 – 2009/01 Ph.D., Faculté de Pharmacie, Université de Montréal, Montreal, Quebec.

2009/02 – 2010/04 Post-doctoral fellow, Faculty of medicine McGill University, Montreal, Quebec 2010/05 – 2012/04 Post-doctoral fellow, School of medicine Indiana University, Indianapolis, Indiana, USA

2011/09 – 2012/05 NIH course Principles of clinical pharmacology formation.

2016/10 APhA Delivering Medication Therapy Management Services; MTM Services, Jefferson University, Philadelphia, PA

2017/04 The Actionable Analytics for Risk Stratification Summit. Financial Research Associates LLC. La Jolla, CA Awards and Distinctions

2001/09 – 2004/12 MDS Pharma Services Studentship Award.

2004/03 – 2007/03 Rx&D Health Foundation Studentship Award (declined).

2004/03 – 2008/03 CIHR Undergraduate Scholarship.

2008/07 AFPC Futur Academic Leader Award.

2008 (Term; 2years) FRSQ Fellowship Scholarship (declined).

2009/05 FESP Dean Honour List.

2009/02 – 2012/02 CIHR Fellowship Scholarship.

2009/02 – 2012/02 Bisby Fellows Award.

2010/06 William Mahon Trainee Presentation Award.

2014/09 – 2018/08 Research Scholarship Junior 1 FRQ-S in partnership with INESSS.


3

Research Experience

2001/09 – 2003/12 Maîtrise ès Sciences Pharmacy

Faculté de Pharmacie, Université de Montréal Montreal, Canada L’utilisation de la dompéridone comme substrat marqueur de l’activité in vitro des CYP3A4 et CYP3A5. Director: Jacques Turgeon, B.Pharm., Ph.D.

2004/01 – 2009/01 Philosophiae Doctor Pharmacy

Faculté de Pharmacie, Université de Montréal Montreal, Canada Étude in vitro et in vivo évaluant le rôle du métabolisme des

médicaments par les CYP450s comme facteurs de variabilité interindividuelle dans la réponse aux médicaments.

Director: Jacques Turgeon, B.Pharm., Ph.D. *The jury ranked my thesis in the top 5th percentile % of theses presented at the University of Montreal.

2009/02 – 2010/04 Post-doctoral fellow

Lady Davis Institute, McGill University. Montreal, Canada Supervisor: Mark Wainberg, B.Sc., Ph.D.

2010/05 – 2012/04 Post-doctoral fellow Division of Clinical Pharmacology, School of medicine, Indiana University. Indianapolis, IN, USA Supervisors: David Flockhart, MD, Ph.D. Zeruesenay Desta, B.Pharm., Ph.D. Professional Experience

2001/09 – 2002/05 Pharmacist, Pharmacie Jean Coutu Sonia Guimont.

2002/05 – 2006/12 Pharmacist, Pharmacie Pascal Monarque & Christian DeBlois.

2007/01 – 2007/03 Pharmacist, Pharmacie Jacques Meilleur.


4

Teaching Experience

2002–2009 CYP450 and Drug-drug interactions (PHM6508). Faculty of Pharmacy, Universite de Montreal, Montreal,

Canada. 2008–2009 Pain pharmacology; Pharmacogenetics. (PHL6035). Faculty of Pharmacy, Universite de Montreal, Montreal,

Canada. 2007–2008 Pharmacology 2; Pharmacology of analgesic drugs (PHM3235). Faculty of Pharmacy, Universite de Montreal, Montreal,

Canada. 2009 Managing end-of-life symptoms; Drug-drug interactions in

palliative care (PAL6110). Faculty of Medicine, Universite de Montreal, Montreal, Canada.

2010/06 Symposium on pharmacogenetics and cardiovascular

disease. Third International Meeting on Pharmacy and Pharmaceutical Sciences. Istanbul, Turkey.

The influence of pharmacogenetics for warfarin dose requirements.

2011/04 Certificate program of predictive and personalized medicine

in daily medical practice. Yeditepe University, Faculty of medicine and Faculty of pharmacy. Istanbul, Turkey. The role of pharmacogenetics for cardiovascular drug effects. A special look at warfarin and clopidogrel.

2011–2016 Pharmacokinetics and Formulation II; Pharmacokinetics

applied for special populations, Pharmacogenetics (SBP2040). Faculty of Pharmacy, Universite de Montreal, Montreal,

Canada.

2012–2016 Biopharmacy Pharmacokinetics; Drug transport, Bioavailability, Pharmacokinetics for special populations (PHM6506). Faculty of Pharmacy, Universite de Montreal, Montreal, Canada.

2012–2015 Drug development; Pharmacogenetics (PHM6110). Faculty of Pharmacy, Universite de Montreal, Montreal, Canada.

2013–2016 Pharmacokinetics and Formulation I; Transporters and Bioavailability (SBP2030).

Faculty of Pharmacy, Universite de Montreal, Montreal, Canada.


5

Teaching Experience (continued)

2013–2015 Advanced pharmaceutical care Gastroenterology;

Pharmacokinetics and liver diseases (PAP1120). Faculty of Pharmacy, Universite de Montreal, Montreal, Canada.

2013/11 Review of pharmacokinetics in small intestine; drug absorption and metabolism (residents in gastroenterology) (GAS8000).

Faculty of Medicine, Universite de Montreal, Montreal, Canada.

2014–2016 Pharmacokinetics and Formulation 1; Route of drugs in the body, Drug metabolism (SBP2030).


2014–2015 Biopharmacy Pharmacokinetics; Metabolism of drugs (PHM6506).


2017/02 Pharmacogenomics; Drug Transporters (PP541). Faculty of Pharmacy, Universite de Montreal, Montreal, Canada.

College of Pharmacy, University of Sciences, Philadelphia, PA 2018/09-12 Pharmacogenetics of Drug metabolism and Transport

(PHA6427) College of Pharmacy, University of Florida, Gainesville, FL Educational Involvement 2014–2016 Member, Review Committee A, Doctoral Research Award,

Canadian Institute of Health Research.

2014–2016 Member, Comité conjoint de la Faculté de Pharmacie,

Université de Montréal

2014/02 Member, Review Committee, Ph.D. scholarship, Montreal

diabetes Research Center.

2015–2016 Member, Review Committee, Ph.D. scholarship, Fonds de

Recherche du Quebec en Santé

2015–2016 Member, CMDP, CHUM

2015–2016 Member, Pedagogic Committee, QeP program, Faculty of

Pharmacy, Université de Montréal

2015–2016 Member, Admission Committee, QeP program, Faculty of

Pharmacy, Université de Montréal


6

Professional Societies

Ordre des Pharmaciens du Québec (No 201261) American Society for Clinical Pharmacology and Therapeutics International Society for the Study of Xenobiotics Canadian Society of Pharmacology and Therapeutics

Research and/or professional activities outside institution

2006 – 2016 Shareholder of InterMED-Rx

2014 – 2018 Consultant; Pharmacokinetic expert for Institut national

d’excellence en santé et en service sociaux (INESSS).

2019 – Reviewer; Grant Competition Canadian Institutes of Health

Research (CIHR), Pharmaceutical Research committee.


7

Presentation as guest speaker

2019/04/04 American Society of Clinical Pharmacology and Therapeutics Webinar series. Pharmacogenomics Community

Conference entitled; From a genotype to multiple phenotypes: Drug-induced and disease-induced phenoconversion.

USA. 2018/09/23 International Congress on Personalized Health Care 2018. Conference entitled; Impact of GSTA1 polymorphisms on the

oral clearance of busulfan in adult patients undergoing hematopoietic stem cell transplantation.

Montreal, Canada. 2018/08/18 2018 PCS 4th Global Pain Conference Conference entitled; Pain management pharmacotherapy in the

context of polypharmacy and drug-drug interactions. Florence, Italy. 2018/07/16 International Conference on Diabetes, Endocrinology and

Metabolism Conference entitled; The impact of type 2 diabetes on CYP450

drug metabolism capacity. Prague, Czech Republic. 2018/03/21 Lake Nona Leadership Council VII Center for Pharmacometrics and systems pharmacology, Research and Academic Center at Lake Nona Conference entitled; CYP450 phenoconversion in patients with

type 2 diabetes: a mechanism for variability in drug response. Orlando, Florida, USA. 2016/12/05 Center for Pharmacometrics and systems pharmacology,

Research and Academic Center at Lake Nona, University of Florida. Conference entitled; Intersubject variability in drug response;

Role of hepatic and extra-hepatic CYP450s. Orlando, Florida, USA. 2016/04/01 CHUM Endocrinology department meeting. Conference entitled; Drug metabolism in patients with type 2

diabetes. Montreal, Quebec, Canada.


8

Presentation as guest speaker(continued) 2012/07/04 4th Summer School on Medicines (SSM4) Conference entitled; Basic concepts in pharmacokinetics. Montreal, Quebec, Canada. 2012/04/21 15th Annual conference of the Association Médicale du

Québec Conference entitled; La Médecine Prédictive et Personnalisée.

Montreal, Quebec, Canada. 2012/04/17 Certificate Program of Predictive and Personalized Medicine

in Daily Medical Practice. Conference entitled; The role of pharmacogenetics for

cardiovascular drug effects. A special look at warfarin and clopidogrel. Yeditepe University, Istanbul, Turkey.

2010/06/10 Third International Meeting on Pharmacy and Pharmaceutical

Sciences. Symposium on Pharmacogenetics and Cardiovascular

diseases. Conference entitled; The influence of PGx for warfarin dose

requirements. Istanbul, Turkey. 2005/09 Scientific conference at the Geriatric Institute of Montreal

Conference entitled; Les interactions médicamenteuses dans le traitement de la douleur. Sponsored by Janssen Ortho Canada.

Montreal, Quebec, Canada.

2004/12 Interdisciplinary formation meeting on opioid dependence/abuse. Mechanisms of drug-drug interactions with CYP450s and intersubject variability in drug-response.

Montreal, Quebec, Canada.


9

Research Funding History

2014/09 – 2018/08 Research Scholar-Junior 1 FRQ-S in partnership with INESSS stopped 2016/09 Intersubject variability in drug response; role of extra-hepatic

drug metabolism, physiopathologic conditions and pharmacogenetics.

Total funding; $303,086

2014/09 – 2017/08 Starting grant for young investigator Junior 1 from Fonds de Recherche du Québec en santé (FRQ-S).


2014/06 – 2015/12 Canadian Foundation for Innovation (CFI) CFI Leader Opportunity funds_Research infrastructure. CYP450 expression and activity quantification platform.

Principal investigator; Veronique Michaud Total funding; $287,500

2014/06 – 2018/05 Fonds Québécois de la Recherche sur la Nature et les et les

Technologies (FQRNT) Synthèse stéréosélective d'arylcyclopropyléthers et étude de

leur stabilité métabolique en presence de cytochromes P450. Principal investigator; Andre Charette

Co-investigators; Alexandre Gagnon, Veronique Michaud Total funding; $48,000 2014/02 – 2015/01 Diabetes Quebec and Montreal Diabetes Research Center

Pilot grant Principal investigator; Veronique Michaud Total funding; $10,000

2014 – 2018 Ministère des Finances et de l’Économie. Fonds de stopped by the Minister 2017 partenariat pour un Québec innovant.

Optimisation des approches thérapeutiques en soins de première ligne : OPTI-THERA

Principal Investigators: Pavel Hamet, Jacques Turgeon

Co-applicants: Johanne Tremblay, Veronique Michaud, Janusz Kaczorowski, Jean Lachaine, Bartha Knoppers

Lyne, Lalonde, Philippe Awadalla Total funding; $18,374,984


10

Research Funding History (continued)

2013/10 – 2017/09 Canadian Institutes of Health Research (CIHR) Effects of Type 2 Diabetes (T2D) on drug disposition and CYP450 activities; a special look at extra-hepatic metabolism.

Principal investigator; Veronique Michaud Co-investigators: Jean-Louis Chiasson, Vincent Poitout, Pavel Hamet Total funding; $507,268

2012/04 – 2017/03 Canadian Institutes of Health Research (CIHR)

The first characterization of functional CYP450 activities in human cardiac myocytes: Modulation of cardiac potassium channel block due to local metabolism of QT-prolonging drugs. Principal investigator; Jacques Turgeon

Co-investigators: Veronique Michaud, Benoit Drolet, Chantal Simard Total funding; $807,020

2012/07 – 2015/06 Heart and Stroke Foundation of Canada (HSFC)

The first characterization of functional CYP450 activities in human cardiac myocytes. Principal investigator; Jacques Turgeon

Co-investigators: Veronique Michaud, Benoit Drolet, Chantal Simard


2012/06 – 2013/05 Rx & D Health Research Foundation Effects of type 2 diabetes on expression and activities of CYP450 drug metabolizing enzymes Principal investigator; Veronique Michaud


2018/01 – 2018/12 Establishment funds College of Pharmacy, University of Florida

Total funding; $500,000 Principal investigator; Veronique Michaud


11

2017 – Palliative Care Research Consortium and Tabula Rasa Healthcare Co-sponsorpship ($500 000)

A Prospective Multicenter Cohort Study to Evaluate the Characteristics and Clinical Implications of Pharmacogenomic Information Relevant to Polypharmacy Actions in Patients with Advanced Illness Who Are Receiving Multiple Drugs for Pain and Other Disorders.

Co-investigators: Janet Bull Russell Portenoy Veronique Michaud Kevin Bain Jacques Turgeon Submitted NIH Grants

Hesperos, Inc and Tabula Rasa HealthCare Partnership Human on a chip evaluation of drug-drug interactions

associated with COVID-19 therapeutics for at risk populations PI: James Hickman Collaborators: Jacques Turgeon, Veronique Michaud Budget: $500,000 to TRHC Submitted, May 2020 Period-of-performance: June 15, 2020 - June 14, 2022

Hesperos, Inc and Tabula Rasa HealthCare Partnership Modulatory Role of Blood-Brain-Barrier and Enzymatic

Activity in an Innovative Human Model of Cholinergic Drug Induced Dementia PI: James Hickman, Jacques Turgeon Collaborators: Michael Schur, Veronique Michaud Budget: $550,000 to TRHC Submitted, April 2020 Period-of-performance Sept. 1, 2020 - August 31, 2022


12

Supervision of Graduate Students

09/2013 –2019/08 Sophie Gravel, M.Sc./Ph.D. in Pharmaceutical Sciences

01/2013 – 2018/08 Yat Hei Leung, Ph.D. in Pharmaceutical Sciences

2015/05 – 2018/01 Valerie Clermont, M.Sc. in Pharmaceutical Sciences

2013/01 – 2017/06 Jennifer Lu, Ph.D. in Pharmaceutical Sciences

2014/08 – 2017/02 Sarah Maximos, MD-M.Sc. in Biomedical Sciences

2014/09 – 2017/05 Alexia Grangeon, M.Sc. in Pharmaceutical Sciences

2015/09 – 2016/08 Roxanne Pelletier, M.Sc. in Pharmaceutical Sciences

Supervision of PharmD student to M.Sc. Residency to pharmacotherapy program

2012/06 – 2012/12 Candidates; Maude Beauchamp-Vien, Émilie Boisvert, Ann-Sophie Payette, Alessandra Stortini Co-supervisor (scientific director)

Project; Evaluation of the relationship between Acid

mycophenolique (MyforTIC®) drug exposure and adverse drug reactions in stable kidney transplant patients.

2012/09 – 2013/12 Candidates; Benoit Crevier, Sami Suhail Jiouni, Jennifer Yee Co-supervisor (scientific director) Project; QTVIE study 2013/09 – 2014/12 Candidates; Yvonne Yeung, Mohammad El-Sakkary, Hao Wang, Ngan Zinquon Scientific director Project; Candy study Supervision of Undergraduate Students

2013/05 – 2013/08 Kathryn Chadwick, B.Sc., Stage, Queen’s University

2014/05 – 2014/09 Nour Ghazal, B.Sc. in Pharmaceutical Sciences, UdM

2014/05 – 2014/09 Roxanne Pelletier, B.Sc. in Pharmaceutical Sciences, UdM

2015/05 – 2015/09 Michel Chamoun, B.Sc. in Pharmaceutical Sciences, UdM

2015/05 – 2015/09 Charles Hosmi, B.Sc. in Pharmaceutical Sciences, UdM 2018/05 – 2018/12 My Tran, PharmD, College of Pharmacy, UF


13

Detailed Publications

Published refereed papers 1) Michaud V, Turgeon J. Cytochrome P450, drug interactions and the treatment of dementia.

Geriatrics and Aging 2003; 6(2):22-7.

2) Simard C, Michaud V, Gibbs B, Massé R, Lessard E, Turgeon J. Identification of the cytochrome P450 enzymes involved in the metabolism of domperidone. Xenobiotica 2004; 34(11/12):1013-23.

3) Turgeon J, Pharand C, Michaud V. Understanding clopidogrel efficacy in the presence of

cytochrome P450 polymorphism. Commentary, Canadian Medical Association Journal 2006; 174(12)1729-30.

4) Michaud V, Mouksassi M-S, Labbé L, Bélanger P-M, Lefebvre M, Gilbert M, Grech-Bélanger

O, Turgeon J. Inhibitory effects of propafenone on the pharmacokinetics of caffeine in man. Therapeutic Drug Monitoring 2006; 28(6):779-83.

5) Michaud V, Simard C, Turgeon J. An improved HPLC assay with fluorescence detection for the determination of domperidone and three major metabolites for application to in vitro drug metabolism studies. J Chromatogr B Analyt Technol Biomed Life Sci. 2007 Jun 1;852(1-2):611-6.

6) Michaud V, Vanier MC, Brouillette D, Roy D, Verret L, Noël N, Taillon I, O’Hara G, Gossard D,

Champagne M, , Goodman K, Renaud Y, Brown A, Phillips M, Ajami A., Turgeon. Combination of phenotype assessments and CYP2C9-VKORC1 polymorphisms in the determination of warfarin dose requirements in heavily medicated patients Clin Pharmacol Ther. 2008 May; 83(5):740-8.

7) Fenneteau F, Turgeon J, Couture L, Michaud V, Li J, Nekka F. Assessing drug distribution in

tissues expressing P-glycoprotein through physiologically based pharmacokinetic modelling: model structure and parameters determination. Theor Biol Med Model. 2009 Jan15; 6:2.

8) Michaud V, Simard C, Turgeon J. Characterization of CYP3A Isozymes involved in the

Metabolism of Domperidone : role of Cytochrome b5 and inhibition by ketoconazole. Drug Metab Lett. 2010 Apr 1; 4(2): 95-103.

9) Michaud V, Turgeon J. Assessement of competitive and mechanism-based inhibition by

clarithromycin: use of domperidone as a CYP3A probe-drug and various enzymatic sources including a new cell-based assay with freshly isolated human hepatocytes. Drug Metab Lett. 2010 Apr 1; 4(2): 69-76.

10) Bar-Magen T, Donahue D.A, McDonough E, Kuhl B.D, Faltenbacher V.H, Xy H, Michaud V,

Sloan R.D, Wainberg M.A. HIV-1 subtype B and C integrase enzymes exhibit differential


14

patterns of resistance to integrase inhibitors in biochemical assays. AIDS. 2010 Sep; 24(14): 2171-9.

Published refereed papers (continued) 11) Michaud V, Dumas M-C, Frappier M, Turgeon J. Determination of relative levels of human

cardiac CYP450 isoforms in patients with heart failure. PLoS One 2010; 5(12):e15666. 12) O’Hara G, Philippon F, Gilbert M, Champagne J, Michaud V, Charbonneau L, Pruneau G,

Hamelin B.A, Geelen P, and Turgeon J. Combined Administration of Quinidine and Propafenone for Atrial Fibrillation: The CAQ-PAF Study. J Clin Pharmacol. 2011 Apr 20; 52(2):171-9 (EPub).

13) Michaud V, Turgeon J, Flockhart D, Wainberg M. Rôle de la pharmacogénétique dans la

réponse au traitement antirétroviral de l’infection par le VIH. Virologie 2011; 15 (3) :157-74. 14) Michaud V, Ogburn E, Kreutz Y , Thong N, Aregbe AO., Quigg TC., Epstein N, Callaghan JT.,

Flockhart DA., Desta Z. Induction of CYP2C19 and CYP3A activities following repeated administration of efavirenz in human. Clin Pharmacol Ther. Mar 2012; 91 (3):475-82.

15) Michaud V, Bar-Magen T, Turgeon J, Desta Z, Flockhart D, Wainberg M. The dual role of

pharmacogenetics in HIV treatment: Mutations and polymorphisms regulating antiretroviral drug resistance and disposition. Pharmacol Rev.2012; 64 (3):803-33.

16) Michaud V, Turgeon J. Domperidone and sudden cardiac death: how much longer should we

wait? J Cardiovasc Pharmacol. 2013 Mar; 61(3):215-7.

17) Skrobik Y, Leger C, Cossette M, Michaud V, Turgeon J. Factors Predisposing to Coma and Delirium: Fentanyl and Midazolam Exposure, CYP3A5, ABCB1 and ABCG2 Genetic Polymorphisms, and Inflammatory Factors. Cri Care Med. 2013 Apr; 41(4):999-1008.

18) Michaud V, Kreutz Y , Skaar T, Ogburn E, Thong N, Flockhart DA., Desta Z. Induction of

omeprazole metabolism by efavirenz as a function of CYP2C19 genotype. Pharmacogenomics J 2013; Apr30: 1-9 (Epub).

19) Madadi P, Amstutz U, Rieder M, Ito S, Fung V, Hwang S, Turgeon J, Michaud V, Koren

G, Carleton BC; CPNDS Clinical Recommendations Group. Clinical practice guideline: CYP2D6 genotyping for safe and efficacious codeine therapy. J Popul Ther Clin Pharmacol 2013; 20(3):e369-96.

20) Lu J, Michaud V, Guilarta Moya L, Gaudette F, Leung YH, Turgeon J. Effects of β-blockers and

tricyclic antidepressants on the activity of human organic anion transporting polypeptide 1A2 (OATP1A2). JPET 2015; 352(3):552-8

21) Shaw K, Amstutz U, Kim R, Lawrence Lesko J.L, Rhoades J, Turgeon J, Michaud V, Hwang S,

Ito S, Carleton B., and the CPNDS clinical recommendation group. Clinical Practice Recommendations on Genetic Testing of CYP2C9 and VKORC1 variants in Warfarin Therapy. Ther Drug Monit 2015.

http://www.ncbi.nlm.nih.gov/pubmed?term=Madadi%20P%5BAuthor%5D&cauthor=true&cauthor_uid=24214521

http://www.ncbi.nlm.nih.gov/pubmed?term=Amstutz%20U%5BAuthor%5D&cauthor=true&cauthor_uid=24214521

http://www.ncbi.nlm.nih.gov/pubmed?term=Rieder%20M%5BAuthor%5D&cauthor=true&cauthor_uid=24214521

http://www.ncbi.nlm.nih.gov/pubmed?term=Ito%20S%5BAuthor%5D&cauthor=true&cauthor_uid=24214521

http://www.ncbi.nlm.nih.gov/pubmed?term=Fung%20V%5BAuthor%5D&cauthor=true&cauthor_uid=24214521

http://www.ncbi.nlm.nih.gov/pubmed?term=Hwang%20S%5BAuthor%5D&cauthor=true&cauthor_uid=24214521

http://www.ncbi.nlm.nih.gov/pubmed?term=Turgeon%20J%5BAuthor%5D&cauthor=true&cauthor_uid=24214521

http://www.ncbi.nlm.nih.gov/pubmed?term=Koren%20G%5BAuthor%5D&cauthor=true&cauthor_uid=24214521

http://www.ncbi.nlm.nih.gov/pubmed?term=Koren%20G%5BAuthor%5D&cauthor=true&cauthor_uid=24214521

http://www.ncbi.nlm.nih.gov/pubmed?term=Carleton%20BC%5BAuthor%5D&cauthor=true&cauthor_uid=24214521

http://www.ncbi.nlm.nih.gov/pubmed?term=CPNDS%20Clinical%20Recommendations%20Group%5BCorporate%20Author%5D

http://www.ncbi.nlm.nih.gov/pubmed/24214521


15

Published refereed papers (continued) 22) Gaudette F, Sirhan-Daneau A, St-Onge M, Turgeon J, Michaud V. Development of a sensitive

method for the determination of oxycodone and its major metabolites noroxycodone and oxymorphone in human plasma by liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2016 Jan 1;1008:174-80

23) Bouchard P, Bilodeau S, Alain K, Vadnais B, Franco M, Turgeon J, Michaud V. Evaluation of

limited sampling methods for oral busulfan pharmacokinetic monitoring in adult patients undergoing hematopoietic stem cell transplantation. Ther Drug Monit. 2016; 38(3):414-8.

24) Turgeon J, Michaud V. Clinical decision support systems: Great promises for better management of patients' drug therapy. Expert Opin Drug Metab Toxicol. 2016; 72 (8):925-31.

25) Huguet J, Lu J, Gaudette F, Chiasson JL, Hamet P, Michaud V, Turgeon J. No Effects of

pantoprazole on the pharmacokinetics of rosuvastatin in healthy subjects. Eur J Pharmacol 2016; 72(8):925-31.

26) Lu J, Grangeon A, Gaudette F, Turgeon J, Michaud V. Effects of tricyclic compounds on the

transport of anti-migraine triptans through human organic anion transporting polypeptide 1A2 (OATP1A2). J Pharmacokinet Exp Ther 2016; 1(2):1-11.

27) Grangeon A, Gravel S, Gaudette F, Turgeon J, Michaud V. Highly sensitive LC-MS/MS

methods for the determination of seven human CYP450 activities using small oral doses of probe-drugs in human. J Chromatogr B Analyt Technol Biomed Life Sci. 2017; 1040:144-58.

28) Turgeon J, Michaud V, Steffen L. The dangers of polypharmacy in elderly patients. Letter to the

Editor: Polypharmacy in the Elderly- when good drugs lead to bad outcomes. A teachable moment (April 24, 2017; E1). JAMA Internal Med 2017;177(10):1544

29) Maximos S, Chamoun M, Gravel S, Turgeon J, Michaud V. Tissue Specific Modulation of

cyp2c and cyp3a mRNA Levels and Activities by Diet-Induced Obesity in Mice: The Impact of Type 2 Diabetes on Drug Metabolizing Enzymes in Liver and Extra-Hepatic Tissues. Pharmaceutics 2017 Sep 26;9(4).

30) Leung YH, Turgeon J, Michaud V. Study of Statin- and Loratadine-Induced Muscle Pain

Mechanisms Using Human Skeletal Muscle Cells. Pharmaceutics 2017 Oct 10;9(4).

31) Gravel S, Chiasson JL, Dallaire S, Turgeon J, Michaud V. Evaluating the impact of type 2 diabetes mellitus on CYP450 metabolic activities: protocol for a case-control pharmacokinetic study. BMJ Open 2018 Feb 8;8(2).






https://www.ncbi.nlm.nih.gov/pubmed/27978469









16

Published refereed papers (continued) 32) Leung YH, Lu J, Belanger F, Turgeon J, Michaud V. Effects of a series of acidic drugs on L-

lactic acid transport by the monocarboxylate transporters MCT1 and MCT4. Current Pharmaceutical Biotechnology. 2018;18(14):1141-50.

33) Cicali B, Michaud V, Knowlton HK, and Turgeon J. 2018. Application of a novel medication-related risk stratification strategy to a self-funded employer populations. Benefits Quaterly. second quarter 2018:34; 49-55.

34) Gaudette F, Hamadjida A, Bédard D, Nuara SG, Gourdon JC, Michaud V, Beaudry F, Huot P.

Development of a selective and sensitive high-performance liquid chromatography-tandem mass spectrometry assay to support pharmacokinetics studies of LY-487,379 in rat and marmoset. J Chromatogr B Analyt Technol Biomed Life Sci 2018: 1093-94:1-7.

35) Huguet J, Gaudette F, Michaud V, Turgeon J. Development and validation of probe drug

cocktails for the characterization of CYP450-mediated metabolism by human heart microsomes. Xenobiotica 2019;49(2):187-99.

36) Clermont V, Grangeon A, Barama A, Lallier M, Malaise J, Turgeon J, Michaud V. Activity and

mRNA expression levels of selected cytochrome P450s in various sections of the human small intestine. Br J Clin Pharmacol 2019;85(6):1367-77.

37) Grangeon A, Clermont V, Barama A, Gaudette F, Turgeon J, Michaud V. Development and

validation of an absolute protein assay for the simultaneous quantification of fourteen CYP450s in human microsomes by LC-MS/MS-based targeted proteomics. J Pharm Biomed Anal 2019;173 :96-107

38) Gravel S, Chiasson JL, Turgeon J, Grangeon A, Michaud V. Modulation of CYP450 activities in patients with type 2 diabetes. Clin Pharmacol Ther 2019;106(6):1280-9.

39) Gravel S, Gaudette F, Chiasson JL, Turgeon J, Michaud V. Use of 4-hydroxycholesterol

plasma concentrations as an endogenous biomarker of CYP3A activity: Clinical validation in patients with type 2 diabetes. Clin Pharmacol Ther 2019;106(4):831-40.

40) Gravel S, Panzini B, Belanger F, Turgeon J, Michaud V. A pilot study towards the impact of

type 2 diabetes on the expression and activities of drug metabolizing enzymes and transporters in human duodenum. Int J Mol Sci 2019;20(13). pii E3257.

41) Michaud V, Tran M, Pronovost B, Bouchard P, Bilodeau S, Alain K, Vadnais B, Franco M,

Belanger F, Turgeon J. Impact of GSTA1 Polymorphisms on Busulfan Oral Clearance in Adult Patients Undergoing Hematopoietic Stem Cell Transplantation. Pharmaceutics 2019;11(9). pii:E440.

42) Turgeon J, Michaud V, Medication Monitor: Decreasing Adverse Drug Events. Today’s

Geriatric Medicine, January/February 2020, Vol. 13 No. 1 P. 8





17

Published refereed papers (continued)

43) Sid-Otmane L, Hamadjida A, Nuara S, Bedard D, Gaudette F, Gourdon J, Michaud V, Beaudry

F, Panisset M, Huot P. Selective metabropic glutamate receptor 2 positive allosteric modulation alleviates psychosis-like behaviors and dyskinesia in the MPTP-lesioned marmoset. Eur J Pharmacol. 2020 Apr 15;873:172957. Epub 2020 Jan 28.

44) Bain K.T, McGain D, Cicali E.J, Knolwton C.H, Michaud V, Turgeon J. Precision medication: An

illustrative case series guiding the clinical application of multi-drug interactions and pharmacogenomics. Clin Case Rep. 2020; 8:305-312.

45) Galiano L, Hinge N, Kurlin K, Michaud V, Turgeon J. Basic mechanisms and clinical relevance

of drug-induced Long QT Syndrome: block of hERG, drug metabolism and drug transport in the heart. Annals Pharmacology Pharmaceutics 2020 Jan 07; 5(2):1176.

46) Al Rihani SB, Deodhar M, Dow P, Turgeon J, Michaud V. Is Dexamethasone a Substrate, an

Inducer, or a Substrate-Inducer of CYP3As? Archives of Pharmacy & Pharmacology Research 2020 Feb 20; 2(4).

47) Bankes DL, Jin H, Finnel S, Michaud V, Knowlton CH, Turgeon J, Stein A. Association of a

Novel Medication Risk Score with Adverse Drug Events and Other Pertinent Outcomes Among Participants of the Programs of All-Inclusive Care for the Elderly. Pharmacy(Basel). 2020 May 20;8(2)

48) Deodhar M, Dow P, Al Rihani SB, Turgeon J, Michaud V. An illustrative case of

phenoconversion due to multi-drug interactions. Clin Case Rep J. 2020;1(3):1–6.

NIH-NCBI Bibliography: https://www.ncbi.nlm.nih.gov/myncbi/1tU2ohzHoy5cyf/bibliography/public/

https://www.ncbi.nlm.nih.gov/pubmed/32443719/




https://www.ncbi.nlm.nih.gov/myncbi/1tU2ohzHoy5cyf/bibliography/public/


18

Submitted refereed papers

1) Yeung YF, Hao W, Zinquon N, El-Sakkary M, Landry S, Michaud V, Ghazal N, Gaudette F, Hetu P-O, Lebouche B, Sheehan N. Atazanavir, Darunavir and Tenofovir Concentrations in Subjects with HIV and Type 2 diabetes mellitus – a pilot study. JAC. Submitted.

2) Michaud V, Dow P, Al-Rihani S, Deodhar M, Arwood M, Turgeon J. Risk of drug-induced Long QT Syndrome associated with the use of repurposed COVID-19 drugs: a systematic review. Submitted April 21, 2020 BMJ open. medRxiv..

3) Michaud V, Deodhar M, Arwood M, Al Rihani SB, Dow P, Turgeon J ACE2 as a Therapeutic Target for COVID-19; its Role in Infectious Processes and Regulation by Modulators of the RAAS System. Submitted June 10 2020, Journal Clinical Medicine

4) Al Rihani SB, Smith MK, PhD, Bikmetov R, PhD, Deodhar M, BPharm, Dow P, Turgeon, J,

Michaud V. Risk of Adverse Drug Events Following the Virtual Addition of COVID-19 Repurposed Drugs to the Drug Regimens of Frail Elderly Adults with Polypharmacy. Submitted June 11 2020, Clin Pharmacol Ther.


19

Published contributions to a collective work and book chapters 1) Hreiche R, Michaud V, Turgeon J. Chapter 3 - The role of ethnicity in managing

cardiovascular patients. In; “Cardiovascular genetics and genomics” Edited by Dan M. Roden. 2009; 33-46.

2) Michaud V. Étude in vitro et in vivo évaluant le rôle du métabolisme des médicaments par les CYP450s comme facteurs de variabilité interindividuelle dans la réponse aux médicaments. Faculté des Études Supérieures de l’Université de Montréal. Les Presses de l’Université de Montréal; PhD. Thesis : 2009.

3) Maximos S, Chamoun M, Gravel S, Turgeon J, Michaud V. In Pharmacokinetics and Drug

metabolism in Canada : The current landscape. Chapter; Tissue Specific Modulation of cyp2c and cyp3a mRNA Levels and Activities by Diet-Induced Obesity in Mice: The Impact of Type 2 Diabetes on Drug Metabolizing Enzymes in Liver and Extra-Hepatic Tissues. MDPI 2018; 174-191.

4) Leung YH, Turgeon J, Michaud V. In Pharmacokinetics and Drug metabolism in Canada : The

current landscape. Chapter; Study of Statin- and Loratadine-Induced Muscle Pain Mechanisms Using Human Skeletal Muscle Cells. MDPI 2018; 161-73.








20

Published abstracts 1) Michaud V, Simard C, Turgeon J. L’utilisation de la dompéridone comme substrat marqueur

de l’activité des CYP3A4 et CYP3A5. Congrès du Club de Recherche Clinique du Québec 2002. Médecine Science 2002;18(2):28.

2) Michaud V, Simard C, Massé R, Turgeon J. Domperidone as a substrate marker drug for

CYP3A4 and CYP3A5. American Society for Clinical Pharmacology and Therapeutics 2003. Clin Pharmacol Ther 2003;73(2):47.

3) Michaud V, Simard C, Massé R, Turgeon J. Domperidone as a probe drug for CYP3A4 and

CYP3A5. Association of Faculties of Pharmacy of Canada and Canadian College of Clinical Pharmacy 2003.

4) Michaud V, Simard C, Massé R, Turgeon J. A search for a substrate marker drug for CYP3A4

and CYP3A5: Domperidone. Canadian Society for Clinical Pharmacology 2003. Can J Clin Pharmacol 2003;10(3):152.

5) Michaud V, Morin N, Brouillette D, Roy D, Verret L, Noel N, Taillon I, O’Hara G, Gossard D,

Champagne M, Vanier M-C, Turgeon J. Génotype ou Phénotype? Leur rôle dans l’individualisation de traitement pour des agents cardiovasculaires. Congrès du Club de Recherche Clinique du Québec 2003. Médecine Science 2003;19(2):18.


Champagne M, Vanier M-C, Turgeon J. Genotype or Phenotype? Role of these strategies for individualized therapy for cardiovascular drugs patients. Canadian Cardiovascular Society 2003. Can J Cardiol 2003;19(Suppl A):171-2.


Champagne M, Vanier M-C, Turgeon J. Comparative genotypic and phenotypic strategies for individualized therapy with warfarin. American Society for Clinical Pharmacology and Therapeutics 2004. Clin Pharmacol Ther 2004; 75(2):P60.

8) Michaud V, Brouillette D, Roy D, Verret L, Noel N, Taillon I, O’Hara G, Gossard D, Champagne

M, Vanier MC, Turgeon J. Phenotypic strategies, a better approach for individualized warfarin therapy. Association of Faculties of Pharmacy of Canada and Canadian College of Clinical Pharmacy 2004.

9) Michaud V, Harvey M, Goodman K, Morin N, Brouillette D, Roy D, Verret L, Noël N, Taillon I,

O’Hara G, Gossard D, Champagne M, Rosati A, Vanier MC, Ajami A, Turgeon J. Warfarin as its own phenotypic probe drug: nomogram for dose prediction in patients. International congress of Clinical Pharmacology and Therapeutics Brisbane 2004.

10) Michaud V, Harvey M, Goodman K, Pastinen T, Phillips M S., Morin N, Brouillette D, Roy D,

Verret L, Noël N, Taillon I, O’Hara G, Gossard D, Champagne M, Vanier MC, Ajami A, Turgeon J. Polymorphismes du CYP2C9 et de VKOR dans l’établissement d’un nomogramme de traitement pour la warfarine. Congrès du Club de Recherche Clinique du Québec 2004. Médecine Science 2004.


21

Published abstracts (continued) 11) Michaud V, Massé R, Turgeon J. CYP2J2 metabolizes domperidone in guinea pig hearts.

American Society for Clinical Pharmacology and Therapeutics 2005. Clin Pharmacol Ther 2005; 77(2):P75


O, Turgeon J. Effet inhibiteur de la propafénone sur l’élimination de la caffeine. Congrès du Club de Recherche Clinique du Québec 2005. Médecine Science 2005; 21(suppl 2) :33.


O, Turgeon J. Effects of propafenone on the pharmacokinetics of caffeine. American Society for Clinical Pharmacology and Therapeutics 2006. Clin Pharmacol Ther 2006; 79(2):21.

14) Michaud V, Massé R, Turgeon J. Inhibitory potency of clarithromycin towards CYP3As.

American Society for Clinical Pharmacology and Therapeutics 2006. Clin Pharmacol Ther 2006; 79(2):77.

15) Michaud V, Turgeon J. Potentiel inhibiteur de la clarithromycine et CYP3As. Congrès du Club

de Recherche Clinique du Québec 2006. Médecine Science 2006; 22(2):139. 16) Michaud V, Harvey M, Goodman K, Morin N, Brouillette D, Roy D, Verret L, Noël N, Taillon I,

O’Hara G, Gossard D, Champagne M, Rosati A, Vanier MC, Ajami A, Simard S, Turgeon J. Polymorphisms in VKOR and phenotype of CYP2C9 contribute to inter-individual variability of warfarin. Canadian Cardiovascular Society 2006. Can. J. Cardiol. 2006, 22(Suppl D):223.

17) Michaud V, Harvey M, Goodman K, Morin N, Brouillette D, Roy D, Verret L, Noël N, Taillon I,

O’Hara G, Gossard D, Champagne M, Rosati A, Vanier MC, Phillips M, Ajami A, Turgeon J. CYP2C9 phenotype and CYP2C9 and VKORC1 genotypes as modulatory factors of warfarin effects in Caucasian patients with multiple drug regimen. American Society for Clinical Pharmacology and Therapeutics 2007. Clin Pharmacol Ther 2007;81(supp1):S92.

18) Michaud V, Vanier M-C, Brouillette D, Roy D, Verret L, Noel N, Taillon I, O’Hara G, Gossard D,

Champagne M, Goodman K, Renaud Y, Brown A, Phillips M, Ajami A M, Turgeon J. CYP2C9 and VKORC1 polymorphisms combined to phenotypic assessments: their role in warfarin dose requirements in a hospitalized, heavily medicated patient population. Human Genome Meeting 2007. P237.

19) Michaud V, Vanier M-C, Brouillette D, Roy D, Verret L, Noel N, Taillon I, O’Hara G, Gossard D,

Champagne M, Goodman K, Renaud Y, Brown A, Phillips M, Ajami A M, Turgeon J. The role of CYP2C9 and VKORC1 polymorphisms combined to CYP2C9 phenotypic assessments to explain intersubject variability in warfarin dose requirements in a hospitalized, heavily medicated patient population. Canadian Society of Clinical Pharmacology 2007. CSCP oral presentation. P132; 43.


22

Published abstracts (continued) 20) Bouchard P, Bilodeau S, Alain K, Vadnais B, Franco M, Busque L, Roy D.C, Michaud V and

Turgeon J. Impact of individual characteristics on oral Busulfan pharmacokinetics in adults patients undergoing hematopoietic stem-cell transplantation. American Society of Hematology. Blood 2007;110:1993.

21) Michaud V, Pronovost B, Bouchard P, Alain K, Bilodeau S, Bélanger F, Roy CD, Busque L,

Vadenais B, Turgeon J. Impact du polymorphisme de la GST-A1 sur le métabolisme du busulfan administré par voie orale lors d’une pré-greffe de moelle osseuse. Congrès du Club de Recherche Clinique du Québec 2007. Médecine Science 2007; 23(suppl 2) :12.

22) Michaud V, Dumas M-C, Turgeon J. Le cœur, un organe doué d’activité métabolique envers

le vérapamil. Congrès du Club de Recherche Clinique du Québec 2007. Médecine Science 2007; 23(suppl 2) :11.

23) Hreiche R, Michaud V, Simard C, Turgeon J, Drolet B. L'effet du dofétilide sur la

repolarisation cardiaque est module par la concentration de glucose et par la diète riche en sucrose. Congrès du Club de Recherche Clinique du Québec 2007. Médecine Science 2007; 23(suppl 2) :1.

24) Hreiche R, Michaud V, Simard C, Turgeon J, Drolet B. Effects of glucose concentration on

repolarization under conditions of drug-induced blokade of Ikr in guinea-pigs fed with a high sucrose diet. Canadian Cardiovascular Congress, Quebec, October 20-24, 2007.

25) Michaud V, Pronovost B, Bouchard P, Alain K, Bilodeau S, Bélanger F, Roy CD, Busque L,

Vadenais B, Turgeon J. Role of the GST-A1 single nucleotide polymorphisms in the metabolism of busulfan administered orally in patients undergoing bone marrow transplantation. The 8th International ISSX Meeting, Sendai, Japan, October 9-12, 2007.P66.

26) Michaud V, Dumas M-C, Hreiche R, Turgeon J. Metabolism of verapamil in the heart. The 8th

International ISSX Meeting, Sendai, Japan, October 9-12, 2007.P. 27) Michaud V, Dumas M-C, Turgeon J. CYP2C8 is involved in the metabolism of verapamil in

human heart microsomes. American Society for Clinical Pharmacology and Therapeutics Meeting, Orlando, April 2-5, 2008. Clin Pharmacol Ther 2008;83(supp1):S34 (PI85).

28) Michaud V, Turgeon J. Assessement of metabolic-intermediate complex formation by

clarithromycin (CLAR) using the CYP3A probe drug domperidone (DOM) and freshly isolated and grown human hepatocytes. American Society for Clinical Pharmacology and Therapeutics Meeting, Orlando, April 2-5, 2008. Clin Pharmacol Ther 2008;83(supp1):S34 (PI84).

29) Michaud V, Turgeon J. Determination of relative levels of human cardiac CYP450 isoforms in

patients with heart failure. American Society for Clinical Pharmacology and Therapeutics Meeting, Orlando, April 2-5, 2008. Clin Pharmacol Ther 2008; 83(supp1):S33 (PI83).


23

Published abstracts (continued) 30) Michaud V, St-Onge M, Sirhan-Daneau A, Turgeon J. Improved HPLC assay for quantitative

analysis of oxycodone, oxymorphone and noroxycodone in human biologiocal fluids. American Society for Clinical Pharmacology and Therapeutics Meeting, Orlando, April 2-5, 2008. Clin Pharmacol Ther 2008; 83(supp1):S33 (PI82).

31) Bouchard P, Bilodeau S, Alain K, Vadnais B, Franco M, Michaud V, Turgeon J. Evaluation of

limited sampling methods for oral busulfan pharmacokinetic monitoring in adult patients undergoing hematopoietic stem cell transplantation. American Society for Clinical Pharmacology and Therapeutics Meeting, Orlando, April 2-5, 2008. Clin Pharmacol Ther 2008;83(supp1):S74 (PIII07).

32) Tonietto E, Cuerrier S. Boyer M, Letarte N, Noël C, Michaud V, Turgeon J. Clinical impact of

drug interactions with chemotherapy metabolized by CYP3As. American Society for Clinical Pharmacology and Therapeutics Meeting, Orlando, April 2-5, 2008. Clin Pharmacol Ther 2008;83(supp1):PII39

33) Michaud V, Dumas M-C, Turgeon J. Domperidone and verapamil are metabolized by human

heart microsomal fractions. International congress of Clinical Pharmacology and Therapeutics, Quebec, July 2008.

34) Michaud V, Frappier M, Bélanger F, Turgeon J. Determination of mRNAs levels of cardiac

CYP450s involved in the metabolism of drugs from a large cohort of heart failure patients. American Society for Clinical Pharmacology and Therapeutics Meeting, Washington, March 18-21, 2009.Clin Pharmacol Ther 2009;85(supp1): (PI13).

35) Sirhan-Daneau A, Michaud V, St-Onge M, Turgeon J. Pharmacokinetics of oxycodone in

extensive and poor metabolizers of CYP2D6 during co-treatment with placebo or quinidine. European ISSX Meeting, Lisbon, Portugal, May 17-20, 2009.

36) Michaud V, Frappier M, Turgeon J. Determination from a large cohort of heart failure

patients of mRNA Levels of cardiac CYP450s involved in the metabolism of drugs.European ISSX Meeting, Lisbon, Portugal, May 17-20, 2009. P76.

37) Michaud V, Frappier M, Turgeon J. Cardiac CYP450 mRNA levels in ischemic and non-

ischemic hearts from a large cohort of patients with end-stage heart failure. Canadian Cardiovascular Congress, Edmonton, Canada, October 24-28 2009. P399-074.

38) Michaud V, Dumas M-C, Frappier M, Turgeon J Relationship between cardiac CYP450 mRNA

levels and verapamil metabolism in human heart microsomes. Canadian Cardiovascular Congress, Edmonton, Canada, October 24-28 2009. P396-071.

39) Michaud V, Shader S, Oliveira M, Colby-Germinario S, Lisovsky I, Wainberg M. Les cellules

épithéliales de l’endocervix agissent à titre de réservoir transitoire dans l’infection des cellules T par le VIH avec un phénotype X4 ou R5. Journée des étudiants Réseau SIDA/MI FRSQ. November 20, 2009.


24

Published abstracts (continued) 40) Michaud V, Skrobik Y, Tarasevych V, Colucci P, Turgeon J. Population pharmacokinetics of

fentanyl during continuous infusion in patients admitted to the intensive care unit. American Society for Clinical Pharmacology and Therapeutics Meeting, Atlanta, March, 2010.

41) Michaud V, Shader S, Lisovsky I, Oliveira M, Wainberg M. Epithelial vaginal cells from

endocervix serve as a transitory reservoir for T cell infection by HIV-1 with the X4 phenotype. American Society for Clinical Pharmacology and Therapeutics Meeting, Atlanta, March, 2010.

42) Huguet J, Michaud V, Turgeon J. In vitro biotransformation of triazolam in human heart

microsomes. American Society for Clinical Pharmacology and Therapeutics Meeting, Atlanta, March, 2010. Clin Pharmacol Ther, 87(Suppl. 1) : S46 (PII-20)

43) Michaud V, Frappier M, Champagne M, Brouillette D, Roy D, Taillon I, O’Hara G, Gossard D,

Godman K, Philips M, Ajami A, Turgeon J. Contribution of CYP4F2 genotypes to the variability of warfarin dose requirements in Caucasian patients. ISSX meeting, Indianapolis, USA, April 2010.

44) Michaud V, Oliveira M, Gaudette F, Turgeon J, Wainberg M. Métabolisme de l’efavirenz dans

les cellules sanguines mononuclées du cordon ombilical (CBMC). Journée VIH-CRCHUM, Montreal. May 18 2010.

45) Michaud V, Schader S, Oliveira M, Colby-Germinario S, Singhroy D, Wainberg M. Effets du pH

sur le processus d’infection par le VIH dans les cellules vaginales de l’endocervix. Journée VIH-CRCHUM, Montreal. May 18 2010.

46) Michaud V, Schader S, Oliveira M, Colby-Germinario S, Sloan R, Wainberg M. Effets de la

progestérone dans le processus de trans-infection du VIH des cellules vaginales de l’endocervix aux cellules T. Journée VIH-CRCHUM, Montreal. May 18 2010.


Godman K, Philips M, Ajami A, Turgeon J. Assessment of the contribution of CYP4F2 genetic polymorphisms on warfarin dose requirements. CSPT meeting, Toronto, Canada, June 2-4 2010. Can J Clin Pharmacol Vol.17 (1);May 2010: 204 (P6) Oral presentation.

48) Sirhan-Daneau A, Michaud V, Manzini C, Schwab R, Demers A, Roy I, Lafrenchi P, Chauny JM,

St-Onge M, Gaudette F, Belanger F, Lavigne G, Turgeon J. Role of CYP2D6 in the pharmacokinetics and pharmacodynamics of oxycodone in healthy volunteers during co-treatment with placebo or quinidine. CSPT meeting, Toronto, Canada, June 2-4 2010. Can J Clin Pharmacol Vol.17(1);May 2010: 211 (P20)

49) Huguet J, Michaud V, Turgeon J. Biotransformation of triazolam in human liver and heart

microsomes. CSPT meeting, Toronto, Canada, June 2-4 2010. Can J Clin Pharmacol Vol.17(1);May 2010: 228 (P55)


25

Published abstracts (continued) 50) Michaud V, Frappier M, Champagne M, Brouillette D, Roy D, Taillon I, O’Hara G, Gossard D,

Godman K, Philips M, Ajami A, Turgeon J. The influence of pharmacogenetics for warfarin dose requirements. Third International Meeting on Pharmacy and Pharmaceutical Sciences. Istanbul, Turkey, June 9-12 2010; PL-15; Symposium on pharmacogenetics and cardiovascular disease.


Godman K, Philips M, Ajami A, Turgeon J. Effects of CYP4F2 genetic polymorphisms on warfarin dose requirements in Caucasian patients initiating therapy. IUPHAR world congress, Copenhagen, Denmark, July 2010.

52) Skrobik Y, Michaud V, Turgeon J. Delirium and coma in the ICU are associated with drug

metabolism and transporter activity. American Thoracic Society 2010. 53) Michaud V, Ogburn E, Thong N, Aregbe AO., Quigg TC., Epstein N, Callaghan JT., Flockhart

DA., Desta Z. Efavirenz induces CYP2C19-hydroxylation and CYP3A4-sulfoxidation of omeprazole. American Society for Clinical Pharmacology and Therapeutics Meeting, Dallas, March, 2011; PIII-41.

54) Michaud V, Ogburn E, Kreutz Y, Thong N, Aregbe AO, Quigg TC, Flockhart DA., Desta Z.

Influence of efavirenz on CYP2C19-dependent hydroxylation of omeprazole related to CYP2C19 genetic polymorphisms. American Society for Clinical Pharmacology and Therapeutics Meeting, Dallas, March, 2011; PI-27.

55) Michaud V, Ogburn E, Thong N, Aregbe AO. Quigg TC, Flockhart DA, Desta Z. Effects of

efavirenz on the stereoselective disposition of omeprazole in healthy subjects. American Society for Clinical Pharmacology and Therapeutics Meeting, Dallas, March, 2011; PIII-42.


Godman K, Philips M, Ajami A, Turgeon J. CYP4F2 genetic polymorphisms affect warfarin dose requirements in polymedicated patients initiating warfarin therapy. American Society for Clinical Pharmacology and Therapeutics Meeting, Dallas, March, 2011; PI-28.

57) Skrobik Y, Michaud V, Leger C, Kubes P, Turgeon J. Delirium and coma in the ICU are

associated with drug metabolism and transporter activity. American Thoracic Society 2011. 58) Michaud V, Ogburn E, Thong N, Aregbe AO, Quigg TC, Flockhart DA, Desta Z. Stereoselective

induction of omeprazole metabolism by efavirenz. Canadian Society of Clinical Pharmacology Meeting, Montreal, May 24-27 2011.

59) Michaud V, Ogburn E, Kreutz Y , Thong N, Aregbe AO, Quigg TC, Flockhart DA, Desta Z.

Induction of omeprazole metabolism by efavirenz as a function of CYP2C19 genotype. Canadian Society of Clinical Pharmacology Meeting, Montreal, May 24-27 2011.

60) Huguet J, Chehade E, Michaud V, Gaudette F, Turgeon J. Functional activity of human heart

microsomes expressing CYP2E1. American Society for Clinical Pharmacology and Therapeutics Meeting, Washington, March 2012; PI-30:pS18.


26

Published abstracts (continued) 61) Huguet J, Michaud V, Gaudette F, Turgeon J. CYP450 functional activities in human heart

microsomes. American Society for Clinical Pharmacology and Therapeutics Meeting, Washington, March 2012; PI-31:pS19.

62) Michaud V, Kreutz Y, Skaar T, Ogburn E, Thong N, Flockhart D, Desta Z. Genotype-based

estimation of CYP2C19 contribution to the elimination of omeprazole in healthy subjects. American Society for Clinical Pharmacology and Therapeutics Meeting, Washington, March 2012; PII-34:pS64.

63) Michaud V, Ogburn E, Thong N, Desta Z. Evaluation of the use of single plasma samples for

determination of omeprazole hydroxylation and sulfoxidation indices to phenotype CYP2C19 and CYP3A under induction drug interactions. American Society for Clinical Pharmacology and Therapeutics Meeting, Washington, March 2012; PII-35:pS64.

64) Leung YH, Lu J, Belanger F, Turgeon J, Michaud V. Drug-transporter interactions : Inhibition

of MCT1 and MCT4 by statins and other acidic drugs. Canadian Society of Pharmacology and Therapeutics Meeting, Toronto, June 2012; 178: #156.

65) Huguet J, Gaudette F, Michaud V, Turgeon J. Functional Activity of CYP450 2J2, 3A5 and 2E1

in Human Heart Ventricles. Canadian Society of Pharmacology and Therapeutics Meeting, Toronto, June 2012; 124; #57.

66) Leung Y. Hei, Lu J, Belanger F, Turgeon J, Michaud V. Interactions médicamenteuses :

inhibition des MCT1 et MCT4 par les statines et autres médicaments acides. Club de Recherches Cliniques du Québec. October 2012; 136 #98.

67) Huguet J, Gaudette F, Michaud V, Turgeon J. Évaluation de l’activité fonctionnelle des

CYP450s dans les microsomes de cœurs humains. Club de Recherches Cliniques du Québec. October 2012; 138 #100.

68) Huguet J, Gaudette F, Michaud V, Turgeon J. Développement d’une approche cocktail pour

étudier l’activité fonctionnelle des CYP2C8, 1A1 et 2D6 dans le cœur humain. 15eme congrès annuel CRCHUM. Montreal. December 18, 2012.

69) Huguet J, Gaudette F, Michaud V, Turgeon J. A probe drug cocktail to study CYP2C8, 1A1 and 2D6 in the human heart. American Society for Clinical Pharmacology and Therapeutics Meeting, Indianapolis, March 2013; 93(Suppl 1):30.

70) Leung YH, Lu J, Belanger F, Turgeon J, Michaud V. Drug-transporter interactions: inhibition of

MCT1 and MCT4 by statins and other acidic drugs. American Society for Clinical Pharmacology and Therapeutics Meeting, Indianapolis, March 2013; 93(Suppl 1):60.

71) Huguet J., Gaudette F., Michaud V., Turgeon J. Functional activity in human heart expressing

CYP1A1, Annual meeting American Society for Pharmacology and Experimental Therapeutics, Boston, April 20-24 2013.


27

Published abstracts (continued) 72) Leung YH, Lu J, Belanger F, Turgeon J, Michaud V. The role of MCT1 and MCT4 in drug-induced

muscle disorders. Annual meeting American Society for Pharmacology and Experimental Therapeutics, Boston, April 20-24 2013.

73) Huguet J, Sharma S, Fulton S, Gaudette F, Michaud V. Effets de diètes riches en gras sur

l’activité des CYP450s hépatiques et extra-hépatiques chez des souris. Club de Recherche Clinique du Quebec, Stoneham, Quebec, Sept 2013.

74) Huguet J, Godoy R, Sharma S, Bélanger F, Gaudette F, Fulton S, Michaud V. Des organes extra-hépatiques doués d’activité métabolique par les CYP450s. Club de Recherche Clinique du Quebec, Stoneham, Quebec, Sept 2013.

75) Leung YH, Lu J, Bélanger F, Turgeon J, Michaud V. Rôle des transporteurs MCT1 et MCT4 dans

les désordres musculaires induits par les statines. Club de Recherche Clinique du Quebec, Stoneham, Quebec, Sept 2013.

76) Huguet J, Gaudette F, Bélanger F, Michaud V, Turgeon J. Intersubject variability of CYP2J2

activity in human heart microsomes. Annual meeting American Society for Pharmacology and Therapeutics, Atlanta, 2014. Clin Pharmacol Ther 2014: 95(1); PI-041: S31.

77) Leung YH, Papillon M, Turgeon J, Michaud V. Statin-specific transport by MCT1 and MCT4.

Annual meeting American Society for Pharmacology and Therapeutics, Atlanta, 2014. Clin Pharmacol Ther 2014: 95(1); PI-038: S29.

78) Lu J, Guilarte Moya LG, Leung YH, Gaudette F, Keiser M, Michaud V, Turgeon J. Inhibition of

the OATP1A2 transporter by tricyclic compounds. Annual meeting American Society for Pharmacology and Therapeutics, Atlanta, 2014. Clin Pharmacol Ther 2014: 95(1); PII-028: S70.

79) Huguet J, Sharma S, Bélanger F, Gaudette F, Fulton S, Michaud V. CYP450 mediated

metabolism in extra-hepatic tissues. Annual meeting American Society for Pharmacology and Therapeutics, Atlanta, 2014. Clin Pharmacol Ther 2014: 95(1); PI-042: S30.

80) Crevier B, Yee J, Jouni S, Therrien R, Mansour S, Nam Nguyen J, Tremblay C, Turgeon J,

Michaud V. QTVIE : Comparison of the QTc interval between an outpatient HIV-infected population on antiretroviral therapy and two large HIV-negative cohorts. American Society for Pharmacology and Therapeutics meeting, Atlanta, 2014. Late-breaking abstract LBII-013.

81) Huguet J, Gaudette F, Bélanger F, Michaud V, Turgeon J. Stereoselective and interindividual

differences in methadone metabolism in human heart microsomes. Annual meeting American Society for Pharmacology and Therapeutics, Atlanta, 2014. Late-breaking abstract LBII-014.

82) Gravel S, Huguet J, Rousseau E, Gaudette F, Turgeon J, Michaud V. CYP450 mediated drug

metabolism in human lung tissue. 19th North American ISSX meeting, San Francisco, October 2014.


28

Published abstracts (continued)

83) Lu J, Grangeon A, Gaudette F, Keiser M, Michaud V, Turgeon J. Effects of tricyclic compounds on almotriptan transport through OATP1A2. 19th North American ISSX meeting, San Francisco, October 2014.

84) Huguet J, Bélanger F, Michaud V, Turgeon J. Impact of CYP2J2*7 on drug metabolism in the

human heart. 19th North American ISSX meeting, San Francisco, October 2014.

85) Pelletier R, Gravel S, Huguet J, Turgeon J, Michaud V. Metabolism of olanzapine in human heart microsomes. Annual meeting American Society for Pharmacology and Therapeutics, New Orleans, 2015: PII-018.

86) Gravel S, Huguet J, Gaudette F, Turgeon J, Michaud V. Iloperidone metabolism in human hearts. Annual meeting American Society for Pharmacology and Therapeutics, New Orleans, 2015: PII-015.

87) Ghazal N, Yeung Y, Z Ngan, Wang H, El-Sakkary M, Bélanger F, Sheehan N, Lebouché B, Turgeon J, Labbé L, Michaud V. Comparison of drug-transporter mRNA expression levels in PBMC from HIV-infected patients with and without diabetes. Annual meeting American Society for Pharmacology and Therapeutics, New Orleans, 2015: PI-031.

88) Lu J, Grangeon A, Gaudette F, Keiser M, Michaud V, Turgeon J. Effects of tricyclic compounds

on naratriptan transport through OATP1A2. Annual meeting American Society for Pharmacology and Therapeutics, New Orleans, 2015, :PI-025

89) Leung YL, Turgeon J, Michaud V. Statin inhibition of lactic acid transport in human skeletal

muscle. Annual meeting American Society for Pharmacology and Therapeutics, New Orleans, 2015: PII-012.

90) Pilote S, Kamaliza J, Turgeon J, Michaud V, Simard C, Drolet B. The effect of intracellular

methadone on hERG current is modulated by the coexpression of the CYP450 isozyme 2B6. Annual meeting American Society for Pharmacology and Therapeutics, New Orleans, 2015: PII-014.

91) Yeung YF, Wang H, Ngan Z, El-Sakkary M, Michaud V, Hétu PO, Lebouché B, Sheehan NL. Evaluating Concentrations of Antiretrovirals: Atazanavir, Darunavir and Tenofovir in Subjects with HIV and Type 2 Diabetes Mellitus - a Pilot Study. 16th International Workshop on the Clinical Pharmacology of HIV and Hepatitis Therapy; May 2015

92) Maximos S, Leung YT, Gravel S, Bélanger F, Gaudette F, Turgeon J, Michaud V. Hepatic and

extra-hepatic CYP450s activity modulation in C57BL/6 mice fed a high-fat diet. 20th North American International Society of the Study of Xenobiotics, Orlando FL, 2015: P208.

93) J Lu, F Gaudette, M Keiser, V Michaud, J Turgeon. Effects of tricyclic compounds on

zolmitriptan transport through OATP1A2. North American meeting of the International Society for the Study of Xenobiotics, Orlando FL, 2015: P250.


29

Published abstracts (continued) 94) Grangeon A, Gaudette F, Turgeon J and Michaud V. Highly sensitive LC-MS/MS methods for

the in vivo assessment of human CYP450 activities using small doses of probe-drugs. North American meeting of the International Society for the Study of Xenobiotics, Orlando FL, 2015: P3.

95) Gravel S, Huguet J, Gaudette F, Turgeon J, Michaud V. Iloperidone metabolism in human

heart micosomal and cytosolic fractions. North American meeting of the International Society for the Study of Xenobiotics, Orlando, 2015: PII-136.

96) Leung YH, Turgeon J, Michaud V. Inhibition of lactic acid efflux by atorvastatin in human

skeletal muscle cells. North American meeting of the International Society for the Study of Xenobiotics, Orlando, 2015: P259.

97) Gravel S, Grangeon A, Gaudette F, Chiasson JL, Dallaire S, Langelier H, Turgeon J, Michaud V. Type 2 diabetes modulates CYP450 metabolic activities. 10th MDRC annual meeting. Montreal, Quebec, 2016. Oral poster (ranked in the top 10%).

98) Gravel S, Grangeon A, Gaudette F, Chiasson JL, Dallaire S, Langelier H, Turgeon J, Michaud V.

Type 2 diabetes modulates CYP450 metabolic activities; an important factor of variability in drug response. American Society for Pharmacology and Therapeutics meeting, San Diego 2016. Late-breaking abstract.

99) Gravel S, Grangeon A, Gaudette F, Belanger F, Chiasson JL, Dallaire S, Langelier H, Turgeon J, Michaud V. Effect du diabete de type 2 sur le metabolism des medicaments par les Cytochromes P450. Annual scientific meeting of Cardiometabolic Health, Diabetes and Obesity Research Network and COLosSUS Congress. Magog-Oford, Quebec, 2017. #51.

100) Clermont V, Grangeon A, Gaudette F, Barama A, Michaud V. Characterization of CYP450 drug metabolism enzymes along the entire small intestine in humans. American Society for Pharmacology and Therapeutics meeting, Washington DC, 2017: PII-027.

101) Grangeon A, Clermont V, Barama A, Gaudette F, Turgeon J, Michaud V. Simultaneous absolute protein quantification method of 14 CYP450s in human intestine by mass-spectrometry-based targeted proteomics. American Society for Pharmacology and Therapeutics meeting, Washington DC, 2017: PII-049.

102) Leung Y, Turgeon J, Michaud V. Loratadine, a potent inhibitor of lactic acid transporters MCT1 and MCT4 in human skeletal muscle cells. American Society for Pharmacology and Therapeutics meeting, Washington DC, 2017: PI-060.

103) Gravel S, Chiasson JL, Dallaire S, Langelier H, Grangeon A, Gaudette F, Belanger F, Turgeon J, Michaud V. Influence of type 2 diabetes on cytochromes P450 mediated drug metabolism. American Society for Pharmacology and Therapeutics meeting, Washington DC, 2017: PI-038 (within the top 20%).


30

Published abstracts (continued) 104) Gravel S, Panzini B, Chiasson JL, Gaudette F, Grangeon A, Turgeon J, Michaud V. Effects of type

2 diabetes on duodenal CYP450 activities. American Society for Pharmacology and Therapeutics meeting, Orlando FL, March 2018: PT-011 & PWIII-004. (Presidential Trainee Award)

105) Michaud V, Cicali B, Verzicco J, Knowlton CH, Turgeon J. Yearly medical expenditure in patients treated with CYP2D6-dependent opioids and impact of concomitant treatment with CYP2D6 substrate or inhibitor drugs. American Society for Pharmacology and Therapeutics meeting, Orlando FL, March 2018: PII-095.

106) Cicali B, Verzicco J, Knowlton CH, Turgeon J, Michaud V. Increased risk medication related problems due to concomitant administration of CYP2D6-dependent opioids and CYP2D6 interacting drugs. American Society for Pharmacology and Therapeutics meeting, Orlando FL, March 2018: PII-032.

107) Michaud V, Turgeon. Pain management pharmacotherapy in the context of polypharmacy and drug-drug interactions. PCS 4th Global Pain Conference, Florence, Italy, August 2018. Oral presentation (08/18/2018).

108) Michaud V, Tran M, Pronovost B, Bouchard P, Bilodeau S, Alain K, Vadnais B, Franco M, Turgeon J. Impact of GSTA1 polymorphisms on the oral clearance of busulfan in adult patients undergoing hematopoietic stem cell transplantation. International Congres of Personalized Health Care 2nd edition, Montreal, Canada, September 2018. Oral presentation (09/25/2018).

109) Tran M, Pronovost B, Bouchard P, Bilodeau S, Alain K, Vadnais B, Franco M, Turgeon J, Michaud V. Influence of GSTA1 Polymorphisms On The Oral Clearance Of Busulfan Using Limited Sampling Methods In Adult Patients Undergoing Hematopoietic Stem Cell Transplantation. American Society for Pharmacology and Therapeutics meeting, Washington DC, March 2019. Clin Pharmacol Ther 2019;105(supp S1): S16 and S27 (PGRN-009 & PT015) (Special Poster Session Pharmacogenomics and Presidential Trainee Award)

110) Gravel S, Gaudette F, Chiasson JL, Turgeon J, Michaud V. Use of 4β-hydroxycholesterol

plasma concentration as an endogenous biomarker of CYP3A activity: Clinical validation in patients with type 2 diabetes. American Society for Pharmacology and Therapeutics meeting, Washington DC, March 2019. Clin Pharmacol Ther 2019;105(supp S1): S58 (PII-058).

111) Michaud V, Lingineni K, Turgeon J, Schmidt S. Physiologically-based pharmacokinetic (PBPK) clopidogrel and its active metabolite when administered alone or during concomitant administration with esomeprazole considering time-dependent inhibition. Clin Pharmacol Ther 2020; 107, (S1) PIII-128.


31

Accepted abstracts

1) Lingineni K, Turgeon J, Schmidt S, Michaud V. PBPK modeling of clopidogrel and its active metabolite when administered alone or during concomitant administration with esomeprazole or ketoconazole. American Society for Pharmacology and Therapeutics meeting, Houston, March 2020.


32

Professional Manuscripts

1) Turgeon J, Michaud V. Le cytochrome P450 et les interactions médicamenteuses. L’Actualité

Médicale 2002; 23 (23):3 -5. 2) Michaud V, Turgeon J. Cytochromes P450 et leur rôle clinique. Le Médecin du Québec 2002;

37(8):73-83. 3) Michaud V, Turgeon J. Cytochrome P450, drug interactions and the treatment of dementia.

Geriatrics and Aging 2003; 6(2):22-7. 4) Turgeon J, Michaud V. Tableaux des principaux substrats d’intérêt pour le traitement de la

douleur. Février 2003.

5) Michaud V, Turgeon J. Angiotensin converting enzyme inhibitors (ACEIs) and Angiotensin II AT1 receptor blockers (ARBs), comparative charts. Mars 2003.

6) Michaud V, Turgeon J. L’importance clinique des interactions médicamenteuses reliées aux

isoenzymes du cytochrome P450: de la fiction à la réalité. Pharmactuel 2003;36(2):88-96. 7) Michaud V, Hreiche R, Turgeon J. Les CYP450 et la gestion des interactions médicamenteuses

dans la pratique quotidienne. L’Actualité Pharmaceutique 2006; formation continue:1-8. 8) Michaud V, Hreiche R, Turgeon J. CYP450 et gestion des interactions médicamenteuses dans

la pratique quotidienne. L’Actualité Médicale 2007;7(5) :49-53. 9) Turgeon J, Michaud V. 1, 2, 3 Prescription; 4, 5, 6 Interactions. Le médecin du Québec. 2008;

43(12) :39-44. 10) Michaud V, Turgeon J. La médecine personnalisée frappe à votre porte. Le médecin du

Québec 2008; 43(12) :75-9. 11) Michaud V, Turgeon J. Inhibiteurs de la pompe à protons, CYP2C19 et clopidogrel, où en

sommes-nous? Pharmactuel 2010; 43 (4) : 222-4.

12) Michaud V, Turgeon J. Les interactions médicamenteuses; fictions ou réalités. Bulletin de la Croix-Bleue du Québec. 2012

curriculum vitae - tabula rasa healthcare€¦ · 2011/04 certificate program of predictive and...

Documents